12:00 AM
Nov 08, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xcytrin motexafin gadolinium: Phase III

PCYC reported data from 25 patients given Xcytrin followed by 10 days of radiation during the open-label lead-in stage of the company's 425-patient U.S. Phase III trial. Patients had an average of 12 brain metastases...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >